Literature DB >> 24476824

In vivo discovery of immunotherapy targets in the tumour microenvironment.

Penghui Zhou1, Donald R Shaffer2, Diana A Alvarez Arias3, Yukoh Nakazaki3, Wouter Pos3, Alexis J Torres4, Viviana Cremasco3, Stephanie K Dougan5, Glenn S Cowley6, Kutlu Elpek7, Jennifer Brogdon8, John Lamb9, Shannon J Turley3, Hidde L Ploegh5, David E Root6, J Christopher Love4, Glenn Dranoff3, Nir Hacohen6, Harvey Cantor3, Kai W Wucherpfennig3.   

Abstract

Recent clinical trials showed that targeting of inhibitory receptors on T cells induces durable responses in a subset of cancer patients, despite advanced disease. However, the regulatory switches controlling T-cell function in immunosuppressive tumours are not well understood. Here we show that such inhibitory mechanisms can be systematically discovered in the tumour microenvironment. We devised an in vivo pooled short hairpin RNA (shRNA) screen in which shRNAs targeting negative regulators became highly enriched in murine tumours by releasing a block on T-cell proliferation upon tumour antigen recognition. Such shRNAs were identified by deep sequencing of the shRNA cassette from T cells infiltrating tumour or control tissues. One of the target genes was Ppp2r2d, a regulatory subunit of the PP2A phosphatase family. In tumours, Ppp2r2d knockdown inhibited T-cell apoptosis and enhanced T-cell proliferation as well as cytokine production. Key regulators of immune function can therefore be discovered in relevant tissue microenvironments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24476824      PMCID: PMC4052214          DOI: 10.1038/nature12988

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  48 in total

Review 1.  Cbl-b in T-cell activation.

Authors:  Magdalena Paolino; Josef M Penninger
Journal:  Semin Immunopathol       Date:  2010-02-21       Impact factor: 9.623

2.  Protein phosphatases and the regulation of mitosis.

Authors:  Francis A Barr; Paul R Elliott; Ulrike Gruneberg
Journal:  J Cell Sci       Date:  2011-07-15       Impact factor: 5.285

3.  Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells.

Authors:  John M Ashton; Marlene Balys; Sarah J Neering; Duane C Hassane; Glenn Cowley; David E Root; Peter G Miller; Benjamin L Ebert; Helene R McMurray; Hartmut Land; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2012-08-02       Impact factor: 24.633

4.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 5.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

6.  Multidimensional analysis of the frequencies and rates of cytokine secretion from single cells by quantitative microengraving.

Authors:  Qing Han; Elizabeth M Bradshaw; Björn Nilsson; David A Hafler; J Christopher Love
Journal:  Lab Chip       Date:  2010-04-08       Impact factor: 6.799

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

9.  Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.

Authors:  C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour
Journal:  Cancer Microenviron       Date:  2012-10-27

10.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

View more
  95 in total

1.  An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Authors:  Casey W Shuptrine; Reham Ajina; Elana J Fertig; Sandra A Jablonski; H Kim Lyerly; Zachary C Hartman; Louis M Weiner
Journal:  Cancer Immunol Immunother       Date:  2017-08-02       Impact factor: 6.968

2.  Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy.

Authors:  Patrick A Ott
Journal:  Ann Transl Med       Date:  2015-11

3.  Functional TCR T cell screening using single-cell droplet microfluidics.

Authors:  Aude I Segaliny; Guideng Li; Lingshun Kong; Ci Ren; Xiaoming Chen; Jessica K Wang; David Baltimore; Guikai Wu; Weian Zhao
Journal:  Lab Chip       Date:  2018-12-04       Impact factor: 6.799

4.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

Review 5.  In vivo RNAi screens: concepts and applications.

Authors:  Shane Crotty; Matthew E Pipkin
Journal:  Trends Immunol       Date:  2015-04-27       Impact factor: 16.687

Review 6.  Targeting PP2A in cancer: Combination therapies.

Authors:  Sahar Mazhar; Sarah E Taylor; Jaya Sangodkar; Goutham Narla
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-01       Impact factor: 4.739

Review 7.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

8.  Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation.

Authors:  Jernej Godec; Glenn S Cowley; R Anthony Barnitz; Ozan Alkan; David E Root; Arlene H Sharpe; W Nicholas Haining
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

Review 9.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

10.  HIV Receives a "One Two Knockout Punch".

Authors:  Conrad Russell Cruz; Catherine M Bollard
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.